* UNITY Biotechnology Inc UBX.OQ UBX.O is expected
to show a
fall in quarterly revenue when it reports results on August 10
(estimated).
*
* Refinitiv's mean analyst estimate for UNITY Biotechnology
Inc
is for a loss of 86 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $8, above its last closing price
of $2.43.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -1.08 -1.08 -0.76 Beat 29.9
Dec. 31 2023 -1.01 -1.05 -1.00 Beat 4.6
Sep. 30 2022 -1.62 -1.65 -1.36 Beat 17.4
Jun. 30 2022 -2.70 -2.80 -1.90 Beat 32.1
Mar. -2.52 -2.57 -2.80 Missed -8.8
31 2022
Dec. 31 2021 -3.06 -3.85 -1.80 Beat 53.2
Sep. 30 2021 -3.77 -3.71 -3.00 Beat 19.2
Jun. 30 2021 -2.91 -3.07 -3.20 Missed -4.1
This summary was machine generated August 8 at 12:04 GMT. All
figures in US dollars unless otherwise stated